Key Points - Blood-borne hepatotropic viruses (hepatitis type B, C and D [HBV, HCV and HDV]) are capable of transmission in athletes of collision/contact sports due to bleeding injuries. - Potentially serious liver complications from HBV, HCV and HDV can be minimized by effective preventive and therapeutic strategies. - Elite athletes with HBV should be virally suppressed, and uninfected subjects should be vaccinated; those participating in collision/contact sports should aim for low viral load and confirmation of vaccine response, respectively. - Remarkable progress has been made in the HCV field and the virus can be cured with 2-3 months of effective, safe, all-oral direct acting antiviral therapy. - Awareness of HDV, which causes rapid disease progression among HBV infected individuals, must improve; a new therapy has recently been approved.
© Copyright 2022 Sports Medicine - Open. Springer Open. Alle Rechte vorbehalten.